[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Aptamer Sciences, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":51},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100568953",false,"NCT06687941","A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors","A Multi-center, Open-label, Dose Escalation and Expansion, Phase 1 Study to Evaluate the Tolerability, Safety and Pharmacokinetics of AST-201 in Patients With GPC3-positive Advanced Solid Tumors","Inclusion Criteria\n\n* Male and female aged ≥19 years\n* Histologically and\u002For cytologically diagnosed as the advanced recurrent solid tumor\n* GPC3-positive confirmed by IHC test\n* At least 1 measurable or non-measurable but evaluable lesion as defined per RECIST v1.1 (modified RECIST for hepatocellular carcinoma)\n* ECOG performance status of 0 or 1\n* Life expectancy at least 12 weeks\n* Adequate hematologic, hepatic, renal, and heart\u002Fcoagulation function\n* Child-Pugh Class of A for HCC\n\nExclusion Criteria\n\n* Subjects with ischemic heart disease\n* Subjects with anti-tumor treatment within 4 weeks\n* Subjects with comorbidities such as uncontrolled hypertension, heart failure, etc.\n* Pregnant or potentially pregnant and lactating woman","ALL","19 Years",{"count":18,"type":19},70,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","This is the first in human trial clinical study of AST-201 in patients with GPC3-positive advanced solid tumors. This study aims to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of AST-201 across various tumor types.",[25,26,27,28],"Neoplasms","Carcinoma, Hepatocellular","Carcinoma, Non-Small-Cell Lung","Liver Neoplasms",[30,31,32,33,34,35,36,37],"Glypican-3 (GPC3)","GPC3-positive advanced solid tumors","AST-201","Aptamer-drug conjugate","Hepatocellular carcinoma (HCC)","Advanced solid tumors","Metastatic","Dose Escalation and Expansion","RECRUITING","2026-03-23",{"date":41,"type":42},"2026-03-27","ACTUAL",{"date":44,"type":42},"2025-03-11",{"date":46,"type":19},"2028-05",{"name":48,"class":49},"Aptamer Sciences, Inc.","INDUSTRY",4,""]